FibroGen(FGEN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

FGEN FibroGen

Trading 12-23 11:50:39 EST

0.4399

+0.0399

+9.98%

High0.4460	Low0.4000	Vol938.49K
Open0.4100	D1 Closing0.4000	Amplitude11.50%
Mkt Cap44.33M	Tradable Cap40.87M	Total Shares100.77M
T/O396.01K	T/O Rate1.01%	Tradable Shares92.91M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"FGEN","market":"US","secType":"STK","nameCN":"FibroGen","latestPrice":0.4399,"timestamp":1734972619780,"preClose":0.4,"halted":0,"volume":938489,"delay":0,"floatShares":92907511,"shares":100770153,"eps":-1.224514,"marketStatus":"Trading","change":0.0399,"latestTime":"12-23 11:50:39 EST","open":0.41,"high":0.446,"low":0.4,"amount":396011.81018305,"amplitude":0.115,"askPrice":0.4459,"askSize":1807,"bidPrice":0.437,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-1.224514,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1734987600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1415941200000,"exchange":"NASDAQ","adjPreClose":0.4,"preHourTrading":{"tag":"盘前","latestPrice":0.41,"preClose":0.4,"latestTime":"09:25 EST","volume":8046,"amount":3155.6545563600002,"timestamp":1734963910060},"postHourTrading":{"tag":"盘后","latestPrice":0.4,"preClose":0.4,"latestTime":"19:25 EST","volume":20296,"amount":8131.1872,"timestamp":1734740750101},"volumeRatio":1.794866,"impliedVol":0.1468,"impliedVolPercentile":0.0916},"requestUrl":"/m/hq/s/FGEN","defaultTab":"news","newsList":[{"id":"2492954742","title":"Analysts Offer Insights on Healthcare Companies: FibroGen (FGEN) and Johnson & Johnson (JNJ)","url":"https://stock-news.laohu8.com/highlight/detail?id=2492954742","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492954742?lang=en_us&edition=fundamental","pubTime":"2024-12-17 21:10","pubTimestamp":1734441011,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on FibroGen (FGEN – Research Report) and Johnson & Jo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-fibrogen-fgen-and-johnson-johnson-jnj?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-fibrogen-fgen-and-johnson-johnson-jnj?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FGEN","LU1032466523.USD","LU1066051498.USD","HCSG","IE0034235303.USD","LU1057294990.SGD","LU1674673691.USD","LU1935042991.SGD","LU1032955483.USD","LU2347655156.SGD","SG9999001440.SGD","BK4568","BK4588","IE00BVYPNW00.USD","LU1162221912.USD","IE00BVYPNV92.GBP","IE00BSNM7G36.USD","LU0640476718.USD","LU1244550577.SGD","LU1674673428.USD","LU2089984988.USD","LU0289739699.SGD","IE00BJJMRZ35.SGD","LU1430594728.SGD","BK4581","JNJ","LU1221951129.SGD","LU1267930813.SGD","LU0234572021.USD","IE000M9KFDE8.USD","LU0122379950.USD","LU1196500208.SGD","LU0114720955.EUR","LU1244550494.USD","LU2133065610.SGD","IE0009355771.USD","IE00B3PB1722.GBP","IE00B19Z3B42.SGD","LU0792757196.USD","LU1261432733.SGD","LU0320765646.SGD","LU0795875086.SGD","IE00B4R5TH58.HKD","LU0466842654.USD","SG9999002224.SGD","IE0002141913.USD","BK4137","BK4505","LU1066051225.USD","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2492951174","title":"FibroGen initiated with a Buy at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2492951174","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492951174?lang=en_us&edition=fundamental","pubTime":"2024-12-17 20:55","pubTimestamp":1734440119,"startTime":"0","endTime":"0","summary":"H.C. Wainwright initiated coverage of FibroGen (FGEN) with a Buy rating and $10 price target The company’s lead asset, FG-3246, is a novel antibody...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fibrogen-initiated-with-a-buy-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fibrogen-initiated-with-a-buy-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4505","FGEN"],"gpt_icon":0},{"id":"2491984697","title":"FibroGen Appoints David DeLucia as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2491984697","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491984697?lang=en_us&edition=fundamental","pubTime":"2024-12-16 22:48","pubTimestamp":1734360498,"startTime":"0","endTime":"0","summary":"An announcement from FibroGen ( ($FGEN) ) is now available. FibroGen has appointed David DeLucia as Chief Financial Officer, succeeding Juan Graham...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/fibrogen-appoints-david-delucia-as-cfo-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/fibrogen-appoints-david-delucia-as-cfo-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4505","FGEN"],"gpt_icon":0},{"id":"2491699972","title":"FibroGen appoints David DeLucia as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2491699972","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491699972?lang=en_us&edition=fundamental","pubTime":"2024-12-16 21:40","pubTimestamp":1734356459,"startTime":"0","endTime":"0","summary":"FibroGen (FGEN) announced the appointment of David DeLucia to CFO, effective December 16, 2024. The company previously announced that Juan Graham w...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fibrogen-appoints-david-delucia-as-cfo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fibrogen-appoints-david-delucia-as-cfo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","BK4139","FGEN"],"gpt_icon":0},{"id":"2491696238","title":"BRIEF-Fibrogen Appoints David Delucia As Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2491696238","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491696238?lang=en_us&edition=fundamental","pubTime":"2024-12-16 21:40","pubTimestamp":1734356404,"startTime":"0","endTime":"0","summary":"BRIEF-Fibrogen Appoints David Delucia As Chief Financial OfficerDec 16 (Reuters) - FibroGen Inc FGEN.O:FIBROGEN APPOINTS DAVID DELUCIA AS CHIEF FINANCIAL OFFICERJUAN GRAHAM STEPS DOWN AS CFO OF FIBROGENSource text: ID:nGNX5h7FHjFurther company coverage: FGEN.O ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241216:nTUASM2BY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FGEN","BK4505"],"gpt_icon":0},{"id":"2491237695","title":"FibroGen Names David DeLucia CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2491237695","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491237695?lang=en_us&edition=fundamental","pubTime":"2024-12-16 21:21","pubTimestamp":1734355295,"startTime":"0","endTime":"0","summary":"FibroGen (FGEN) said Monday that David DeLucia has been named chief financial officer, effective immediately.DeLucia succeeds Juan Graham, who stepped down on Sunday, the company said.DeLucia most rec","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","FGEN","BK4505"],"gpt_icon":0},{"id":"2491693788","title":"FibroGen Inc - Juan Graham Steps Down as CFO of FibroGen","url":"https://stock-news.laohu8.com/highlight/detail?id=2491693788","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491693788?lang=en_us&edition=fundamental","pubTime":"2024-12-16 21:05","pubTimestamp":1734354300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241216:nTUASM2BY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FGEN","BK4139","BK4505"],"gpt_icon":0},{"id":"2491470693","title":"FibroGen Appoints David Delucia as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2491470693","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491470693?lang=en_us&edition=fundamental","pubTime":"2024-12-16 21:05","pubTimestamp":1734354300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241216:nTUASM2BY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FGEN","BK4505"],"gpt_icon":0},{"id":"2491693228","title":"Press Release: FibroGen Appoints David DeLucia as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2491693228","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491693228?lang=en_us&edition=fundamental","pubTime":"2024-12-16 21:05","pubTimestamp":1734354300,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO, Dec. 16, 2024  -- FibroGen, Inc.  today announced the appointment of David DeLucia to Chief Financial Officer , effective December 16, 2024. The company previously announced that Juan Graham would step down on December 15, 2024.Reporting to Chief Executive Officer Thane Wettig, DeLucia will lead and oversee FibroGen's global finance organization. He has most recently served as FibroGen's Vice President, Head of Corporate Financial Planning and Analysis, Investor Relations, and Treasury.FibroGen, Inc. is a biopharmaceutical company focused on accelerating the development of novel therapies at the frontiers of cancer biology. Roxadustat  is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease  patients on dialysis and not on dialysis. Roxadustat is in clinical development for chemotherapy-induced anemia  and a Supplemental New Drug Application  has been accepted for review by the China Health Authori","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4555","BK4162","ADC","BK4231","R","BK4588","BK4505","WRD","03160","PHH","BK4022","TM","BK4080","CFO","BK4232","BK4585","CIA","FGEN","BK4139","BK4099"],"gpt_icon":0},{"id":"2484940619","title":"FGEN Boosts Shareholder Value with Share Buyback","url":"https://stock-news.laohu8.com/highlight/detail?id=2484940619","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484940619?lang=en_us&edition=fundamental","pubTime":"2024-11-18 15:16","pubTimestamp":1731914168,"startTime":"0","endTime":"0","summary":"Foresight Environmental Infrastructure Limited GBP (GB:FGEN) has released an update. Foresight Environmental Infrastructure Limited (FGEN) has repu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/fgen-boosts-shareholder-value-with-share-buyback?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/fgen-boosts-shareholder-value-with-share-buyback?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1814569148.SGD","BK4551","LU2087625088.SGD","SG9999017495.SGD","BK4022","LU1064131342.USD","BK4139","BK4585","LU0353189680.USD","LU0106261372.USD","SG9999014914.USD","IE00B7SZLL34.SGD","UBER","LU0353189763.USD","LU1988902786.USD","SG9999018857.SGD","LU1316542783.SGD","BK4230","SGXZ31699556.SGD","LU0006306889.USD","BK4588","IE00B19Z3B42.SGD","BK4535","LU0127658192.USD","SG9999014880.SGD","BK4505","FGEN","BK4550","GB00BDT5M118.USD","BK4536","SG9999015952.SGD","SG9999018865.SGD","LU1983260115.SGD","LU0719512351.SGD","SG9999015945.SGD","IE0002270589.USD","SG9999014906.USD","IE00BZ199S13.USD","LU0642271901.SGD","BK4503","LU2264538146.SGD","IE00B19Z3581.USD","SG9999015978.USD","SG9999015986.USD","SG9999014898.SGD","LU0082616367.USD"],"gpt_icon":0},{"id":"2483328599","title":"FibroGen Third Quarter 2024 Earnings: Beats Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2483328599","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483328599?lang=en_us&edition=fundamental","pubTime":"2024-11-15 18:04","pubTimestamp":1731665043,"startTime":"0","endTime":"0","summary":"NasdaqGS:FGEN Earnings and Revenue Growth November 15th 2024. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates by 33%. Earnings per share  also surpassed analyst estimates by 26%.Looking ahead, revenue is expected to decline by 1.4% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 22%.The company's shares are up 18% from a week ago.You should always think about risks. Case in point, we've spotted   6 warning signs for FibroGen  you should be aware of, and 2 of them don't sit too well with us.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fibrogen-third-quarter-2024-earnings-100403150.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["FGEN"],"gpt_icon":0},{"id":"2483719887","title":"Q3 2024 FibroGen Inc Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2483719887","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483719887?lang=en_us&edition=fundamental","pubTime":"2024-11-13 23:22","pubTimestamp":1731511331,"startTime":"0","endTime":"0","summary":"David Delucia; Vice President, Corporate FP&A and Investor Relations; FibroGen Inc. Thank you, Dave. Good afternoon, everyone and welcome to our third quarter, 2024 earnings call on today's call. I will highlight our current strategy for the company and the exciting opportunity for FG-3246 and FG-3180. Our first in class antibody drug conjugate targeting CD-46 and our PET imaging agent in metastatic castration-resistant prostate cancer.I will also highlight the continued strong performance of Roxadustat in China and the potential for Roxadustat development for the treatment of anemia due to lower-risk myelodysplastic syndrome. Then Juan Graham, our CFO will review the financials after which we will open the call for your questions on slide 3. I would like to highlight the strategic strat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q3-2024-fibrogen-inc-earnings-152211383.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AZN","FGEN"],"gpt_icon":0},{"id":"2483026515","title":"FibroGen Inc (FGEN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Cost Reductions","url":"https://stock-news.laohu8.com/highlight/detail?id=2483026515","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483026515?lang=en_us&edition=fundamental","pubTime":"2024-11-13 15:21","pubTimestamp":1731482476,"startTime":"0","endTime":"0","summary":"Total Revenue: $46.3 million in Q3 2024, a 15% increase from $40.1 million in Q3 2023.Roxadustat Net Product Revenue in China: $46.2 million in Q3 2024, a 57% increase from $29.4 million in Q3 2023.Total Roxadustat Net Sales in China: $96.6 million in Q3 2024, a 25% increase from $77.1 million in Q3 2023.Operating Costs and Expenses: $63.1 million in Q3 2024, a 39% decrease from $103.6 million in Q3 2023.R&D Expenses: $21.7 million in Q3 2024, a 65% decrease from $61.2 million in Q3 2023.G&A Expenses: $17.6 million in Q3 2024, a 31% decrease from $25.6 million in Q3 2023.Net Loss: $17.1 million in Q3 2024, compared to a net loss of $63.6 million in Q3 2023.Cash, Cash Equivalents, and Accounts Receivable: $160 million as of September 30, 2024.Guidance for Full Year 2024 China Net Product Revenue: Between $135 million and $150 million.Guidance for Roxadustat Net Sales in China: Revised to $330 million to $360 million for full year 2024.GuruFocus has detected 7 Warning Signs with FGEN.Fib","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/feNwACyP4SUraGaRUWiNrg--~B/aD0yMDA7dz0yMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/28c32977f08a4e25cf73a92bdc305063","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/feNwACyP4SUraGaRUWiNrg--~B/aD0yMDA7dz0yMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/28c32977f08a4e25cf73a92bdc305063"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fibrogen-inc-fgen-q3-2024-072116240.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["FGEN"],"gpt_icon":0},{"id":"2483067889","title":"FibroGen Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2483067889","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483067889?lang=en_us&edition=fundamental","pubTime":"2024-11-13 07:28","pubTimestamp":1731454091,"startTime":"0","endTime":"0","summary":"FibroGen Inc reports results for the quarter ended September 30 - Earnings SummaryFibroGen Inc FGEN.OQ reported a quarterly adjusted loss of 17 cents per share for the quarter ended September 30, high","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nL8N3MJ39Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FGEN"],"gpt_icon":0},{"id":"2483099756","title":"FibroGen (FGEN) Reports Q3 Loss, Tops Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2483099756","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483099756?lang=en_us&edition=fundamental","pubTime":"2024-11-13 07:10","pubTimestamp":1731453012,"startTime":"0","endTime":"0","summary":"FibroGen  came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.52 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 55.26%. A quarter ago, it was expected that this biotech drug developer would post a loss of $0.26 per share when it actually produced a loss of $0.16, delivering a surprise of 38.46%.Over the last four quarters, the company has surpassed consensus EPS estimates two times.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Drugs is currently in the top 27% of the 250 plus Zacks industries. Our research shows that the top 50% of","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/64vRzkiY9LXGPrpW4r2GRQ--~B/aD00Njc7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b95cfdd8768bc3c4620e666dbcb0b248","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/64vRzkiY9LXGPrpW4r2GRQ--~B/aD00Njc7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b95cfdd8768bc3c4620e666dbcb0b248"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fibrogen-fgen-reports-q3-loss-231012148.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["FGEN"],"gpt_icon":0},{"id":"2483066978","title":"FibroGen: Q3 Earnings Snapshot","url":"https://stock-news.laohu8.com/highlight/detail?id=2483066978","media":"Associated Press Finance","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483066978?lang=en_us&edition=fundamental","pubTime":"2024-11-13 06:06","pubTimestamp":1731449198,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO  — SAN FRANCISCO  — FibroGen Inc.  on Tuesday reported a loss of $17.1 million in its third quarter.On a per-share basis, the San Francisco-based company said it had a loss of 17 cents.The biotech drug developer posted revenue of $46.3 million in the period.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fibrogen-q3-earnings-snapshot-220638597.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["FGEN"],"gpt_icon":0},{"id":"2483506480","title":"FibroGen Q3 2024 GAAP EPS $(0.17) Beats $(0.38) Estimate, Sales $46.333M Beat $34.763M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2483506480","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483506480?lang=en_us&edition=fundamental","pubTime":"2024-11-13 05:30","pubTimestamp":1731447033,"startTime":"0","endTime":"0","summary":"FibroGen (NASDAQ:FGEN) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.38) by 55.26 percent.  The company reported quarterly sales of $46.333 million which beat the analyst","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41920574/fibrogen-q3-2024-gaap-eps-0-17-beats-0-38-estimate-sales-46-333m-beat-34-763m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"FibroGen Q3 2024 GAAP EPS $(0.17) Beats $(0.38) Estimate, Sales $46.333M Beat $34.763M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FGEN"],"gpt_icon":0},{"id":"2483529830","title":"BRIEF-FibroGen Q3 EPS USD -0.17","url":"https://stock-news.laohu8.com/highlight/detail?id=2483529830","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483529830?lang=en_us&edition=fundamental","pubTime":"2024-11-13 05:05","pubTimestamp":1731445549,"startTime":"0","endTime":"0","summary":"BRIEF-FibroGen Q3 EPS USD -0.17\n\n\nNov 12 (Reuters) - FibroGen Q3 net income USD -17.084 million.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nPLX4DEE15:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FGEN"],"gpt_icon":0},{"id":"2483063679","title":"FibroGen Inc: Expect Our Cash, Cash Equivalents and Accounts Receivable to Be Sufficient to Fund Our Operating Plans Into 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2483063679","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483063679?lang=en_us&edition=fundamental","pubTime":"2024-11-13 05:05","pubTimestamp":1731445509,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nTUA5LCGH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FGEN","BK4505","BK4139"],"gpt_icon":0},{"id":"2482459495","title":"FibroGen Inc  expected to post a loss of 30 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2482459495","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482459495?lang=en_us&edition=fundamental","pubTime":"2024-11-09 05:40","pubTimestamp":1731102010,"startTime":"0","endTime":"0","summary":"FibroGen Inc  expected to post a loss of30cents a share - Earnings Preview FibroGen Inc FGEN.OQ FGEN.O is expected to show a fall in quarterly revenue when it reports  results on November 12 for the p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nL8N3MF3S1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FGEN"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fibrogen.com","stockEarnings":[{"period":"1week","weight":0.2016},{"period":"1month","weight":0.1429},{"period":"3month","weight":-0.021},{"period":"6month","weight":-0.646},{"period":"1year","weight":-0.4237},{"period":"ytd","weight":-0.5487}],"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0403},{"period":"6month","weight":0.0857},{"period":"1year","weight":0.2506},{"period":"ytd","weight":0.2437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.8,"avgChangeRate":0.224999},{"month":2,"riseRate":0.4,"avgChangeRate":-0.020367},{"month":3,"riseRate":0.2,"avgChangeRate":-0.04263},{"month":4,"riseRate":0.2,"avgChangeRate":-0.156175},{"month":5,"riseRate":0.5,"avgChangeRate":-0.028376},{"month":6,"riseRate":0.7,"avgChangeRate":0.024463},{"month":7,"riseRate":0.5,"avgChangeRate":-0.068735},{"month":8,"riseRate":0.3,"avgChangeRate":-0.058172},{"month":9,"riseRate":0.4,"avgChangeRate":-0.013866},{"month":10,"riseRate":0.5,"avgChangeRate":-0.068025},{"month":11,"riseRate":0.8,"avgChangeRate":0.107257},{"month":12,"riseRate":0.6,"avgChangeRate":0.075426}],"exchange":"NASDAQ","name":"FibroGen","nameEN":"FibroGen"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"FibroGen(FGEN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest FibroGen(FGEN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"FibroGen,FGEN,FibroGen股票,FibroGen股票老虎,FibroGen股票老虎国际,FibroGen行情,FibroGen股票行情,FibroGen股价,FibroGen股市,FibroGen股票价格,FibroGen股票交易,FibroGen股票购买,FibroGen股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"FibroGen(FGEN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest FibroGen(FGEN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction